Twist Bioscience Corporation (NASDAQ:TWST) Receives Consensus Rating of "Moderate Buy" from Analysts

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the ten research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $50.40.

TWST has been the topic of several research reports. Robert W. Baird cut their price target on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Guggenheim reaffirmed a "buy" rating and set a $50.00 price objective on shares of Twist Bioscience in a research note on Tuesday, May 6th. Barclays dropped their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. The Goldman Sachs Group dropped their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th.

Twist Bioscience Stock Performance

NASDAQ:TWST traded up $0.43 during midday trading on Wednesday, hitting $38.11. The company's stock had a trading volume of 445,333 shares, compared to its average volume of 966,972. Twist Bioscience has a fifty-two week low of $27.12 and a fifty-two week high of $60.90. The firm's 50 day moving average is $33.49 and its 200-day moving average is $40.19. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.51 and a quick ratio of 4.24. The firm has a market cap of $2.28 billion, a P/E ratio of -11.73 and a beta of 2.41.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 33.48% and a negative net margin of 54.98%. The business had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. Equities analysts anticipate that Twist Bioscience will post -2.12 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Emily M. Leproust sold 5,042 shares of the stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $37.65, for a total transaction of $189,831.30. Following the transaction, the chief executive officer owned 655,432 shares in the company, valued at $24,677,014.80. This trade represents a 0.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Dennis Cho sold 689 shares of the stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $37.65, for a total value of $25,940.85. Following the transaction, the insider owned 110,849 shares in the company, valued at $4,173,464.85. This trade represents a 0.62% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 21,911 shares of company stock worth $761,826. Insiders own 3.01% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Twist Bioscience by 186.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock valued at $95,883,000 after purchasing an additional 1,588,587 shares in the last quarter. First Light Asset Management LLC purchased a new position in Twist Bioscience in the 4th quarter valued at $56,984,000. EdgePoint Investment Group Inc. purchased a new position in Twist Bioscience in the 1st quarter valued at $43,705,000. Marshall Wace LLP lifted its holdings in Twist Bioscience by 15,927.8% in the 4th quarter. Marshall Wace LLP now owns 846,107 shares of the company's stock valued at $39,319,000 after purchasing an additional 840,828 shares in the last quarter. Finally, Nuveen LLC purchased a new position in Twist Bioscience in the 1st quarter valued at $31,960,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.